THERAPEUTIC AREAS

• Obesity Clinical Research: Patient Recruitment Challenges

  Obesity trials face enrollment hurdles. Learn how data-driven insights, patient-first strategies, and decentralized models can break barriers, ease burden, and accelerate timelines.

• Hematology Clinical Development

  Hematology trials need strategies for complex endpoints, advanced therapies, and global compliance. Predictive analytics and tailored approaches accelerate timelines and optimize recruitment.

• Cardiovascular, Renal And Metabolic Clinical Development

  CVRM trials must address comorbidities and complex needs. See how real-world data and expertise improve design, speed recruitment, and advance cardiovascular, renal, and metabolic care.

• Driving Success In Dermatology Drug Development

  Our dedicated teams are led by in-house, board-certified dermatologists who have decades of experience conducting early and late phase studies. Download the available datasheet to learn more.

• Transforming PAH Trials For Patient-Centric Care

  PAH trials need patient-focused strategies. See how innovative designs, digital tools, and real-world data can simplify recruitment, reduce complexity, and improve outcomes in this challenging space.

• A Strategic Approach To CAGT Study Conduct And Operations

  Cell and gene therapy clinical trials require adaptive regulatory and operational strategies to address complex challenges, streamline patient engagement, and support successful development and delivery.

• Advancing Alzheimer's Disease Therapies

  By uniting scientific innovation with patient-focused execution, the next generation of alzheimer’s disease (AD) therapies has the potential to deliver a transformative impact on global health.

• Navigating Autoimmune Disease A Playbook For Cell And Gene Therapies

  By integrating site readiness, patient engagement, and data-driven decision-making, the cell and gene therapies (CAGT) field is advancing toward therapies that not only control disease but transform lives.

• Transforming Medicine: Strategies In CAGT Development

  As cell and gene therapies (CAGTs) evolve, adaptive strategies are crucial to accelerating development and ensuring timely patient access.

• Pioneering Strategies For Early-Phase Oncology Trials

  As the field advances, adaptive methodologies and regulatory shifts redefine early-phase oncology trials, promoting efficiency, flexibility, and equitable access.

• The Next Frontier In Early Phase Oncology Trials

  This session explores the pivotal role of First-in-Human and early phase oncology trials in drug development, emphasizing the importance of comprehensive planning for successful execution.

• Radiation Therapy Quality Assurance In Clinical Trials

  Here, the authors describe the crucial role of radiation therapy in oncology trials and how a robust quality management program can enhance treatment outcomes and research efficacy.

• Top 5 Challenges For Pursuing IO Therapy Clinical Trials

  By leveraging tailored approaches to tackle scientific and operational challenges, sponsors can enhance trial efficiency and advance the development of groundbreaking therapies.

• Clinical Leader Solutions Expo: Early-Phase Oncology Trials (CRO)

  Oncology has been and continues to be the leading priority in global drug development. 44% of all Phase I-III trials, current and planned, are tackling oncology.

• Planning For High-Performance Hematologic Oncology Clinical Trials

  Running successful clinical trials in hematologic malignancies necessitates a deep comprehension of a swiftly evolving treatment framework that is growing more nuanced, intricate, and patient-centered.

• Study Start-Up And Enrollment

  IQVIA Biotech was approached by a clinical-stage biopharmaceutical company to run its Phase II prostate cancer drug trial in the U.S. For more information, download the available case study.

• Achieving Recruitment Objectives In Dermatology Trial: Reducing Timeline And Cost

  IQVIA Biotech was selected to help a U.S. biopharmaceutical company examine the safety and efficacy of its investigational therapy for the treatment of moderate-to-severe hidradenitis suppurativa (HS), a chronic skin condition that causes small, but painful lumps under the skin. This case study will highlight IQVIA Biotech’s unique strategies for site selection and centralized recruitment approach to drive enrollment.

• Leveraging Immunotherapy Expertise to Exceed Customer Goals

  A biologics company needed a CRO with oncology experience that could support protocol design and accelerate the start-up process to meet a quick first-patient-in (FPI) milestone. In this case study, discover how this partner evaluated the safety and pharmacokinetic (PK) profile of an immunotherapeutic drug in subjects with advanced solid tumors.

• The ROI Of IQVIA Site Payments

  This short video explains how and why business process outsourcing (BPO) using IQVIA Technologies for site payments offers excellent ROI for sponsors and peace of mind for sites and investigators.